Intra-Cellular Therapies Stock Price. Everything You Need To Know About The Intra-Cellular Therapies Stock!
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 561 full-time employees. The company went IPO on 2014-01-31. The firm is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellularsignaling mechanisms within the central nervous system (CNS). The Company’s product CAPLYTA is a treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or valproate. The efficacy of CAPLYTA 42 mg in bipolar depression was demonstrated in two positive Phase III placebo-controlled bipolar depression studies, which evaluated the effects of CAPLYTA on depression in adult patients with bipolar I or bipolar II disorder both as monotherapy (Study 404) and as adjunctive therapy with lithium or valproate (Study 402).
Intra-Cellular Therapies Stock Price. Everything You Need To Know About The Intra-Cellular Therapies Stock! performance
- Employees 561
- Company HQ New York City
- Website https://www.intracellulartherapies.com/
- ITCI Asset Type Common Stock
- ITCI Market Capitalization 7.6B
- Earnings Per Share -1.46
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
Intra-Cellular Therapies is a biopharmaceutical company that focuses on the development of novel drugs to treat central nervous system disorders. If you are a retail investor from Malaysia, Thailand, Indonesia, or Vietnam and are interested in investing in this stock, here’s how you can get started. First, it is important to do thorough research on Intra-Cellular Therapies. Look for relevant news, press releases, and financial reports to gain a deeper understanding of the company’s performance and potential growth prospects. Next, consider opening an investment account with a reputable brokerage firm that allows investors from your respective country. Ensure the brokerage offers access to US stock markets, as Intra-Cellular Therapies is listed on the Nasdaq. Before making any investment decisions, assess your risk tolerance and financial goals. Determine how much you are willing to invest and for how long. It is advisable to diversify your portfolio by investing in different sectors and companies. Finally, keep yourself updated with the latest news and developments related to Intra-Cellular Therapies to make informed decisions. Attend webinars, read research reports, and leverage Zorion’s investment insights and recommendations to aid your decision-making process. Remember, investing in stocks involves risks, and it is crucial to consult with a financial advisor or professional before making any investment decisions.
